The Medical Letter on Drugs and Therapeutics
Plecanatide (Trulance) for Chronic Idiopathic Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess), another guanylate cyclase-C receptor agonist, and lubiprostone (Amitiza), a chloride channel activator, were approved earlier for treatment of CIC in adults.1

CHRONIC IDIOPATHIC CONSTIPATION — Symptoms of CIC include infrequent bowel movements (typically <3 defecations per week), straining when defecating, lumpy or hard stools, a sensation of anal blockage or incomplete evacuation, and a need for manual maneuvers to aid defecation.2

Dietary changes (increased fiber and water intake) and bulk-forming laxatives are usually tried first. When these fail, osmotic laxatives such as polyethylene glycol and stimulant laxatives such ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Plecanatide (Trulance) for Chronic Idiopathic Constipation
Article code: 1519c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian